The VEGFR2 based targeted UCAs can contact and combine with the VEGFR2 on the blood vessels when they enter and flow through the tumor’s vessels, forming focal contrast agent accumulation, and can display focal enhanced imaging at ultrasound scanning. This evidence concerns the gene KDR and neoplasm.